Cargando…

Critical appraisal of the use of regorafenib in the management of colorectal cancer

The lack of valid clinical management options for patients affected by metastatic colorectal cancer, which has progressed after all approved standard treatments, has lead to research into new active molecules. Regorafenib is an oral small-molecule multi kinase inhibitor, binding to several intracell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Festino, Lucia, Fabozzi, Alessio, Manzo, Anna, Gambardella, Valentina, Martinelli, Erika, Troiani, Teresa, De Vita, Ferdinando, Orditura, Michele, Ciardiello, Fortunato, Morgillo, Floriana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628528/ https://www.ncbi.nlm.nih.gov/pubmed/23610528 http://dx.doi.org/10.2147/CMAR.S34281

Ejemplares similares

Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
por: Morgillo, Floriana, et al.
Publicado: (2011)

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care
por: Martinelli, Erika, et al.
Publicado: (2007)

Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment
por: Martinelli, Erika, et al.
Publicado: (2017)

Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the COVID-19 Pandemic
por: Napolitano, Stefania, et al.
Publicado: (2022)

Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer
por: Belli, Valentina, et al.
Publicado: (2017)

Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC
por: Ciaramella, Vincenza, et al.
Publicado: (2019)

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells
por: Della Corte, Carminia Maria, et al.
Publicado: (2015)

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
por: Troiani, Teresa, et al.
Publicado: (2016)

Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation
por: Napolitano, Stefania, et al.
Publicado: (2017)

Role and targeting of anaplastic lymphoma kinase in cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2018)

Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
por: Caputo, Vincenza, et al.
Publicado: (2022)

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines
por: Vitiello, Pietro Paolo, et al.
Publicado: (2019)

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells
por: Napolitano, Stefania, et al.
Publicado: (2017)

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Correction: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Corte, Carminia Maria Della, et al.
Publicado: (2022)

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
por: De Vita, Ferdinando, et al.
Publicado: (2016)

Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass
por: Orditura, Michele, et al.
Publicado: (2007)

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
por: Morgillo, Floriana, et al.
Publicado: (2017)

Towards the era of precision medicine in metastatic colorectal cancer
por: Napolitano, Stefania, et al.
Publicado: (2020)

Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Vanvitelli’
por: De Falco, Vincenzo, et al.
Publicado: (2020)

Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models
por: Belli, Valentina, et al.
Publicado: (2019)

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets
por: Martini, Giulia, et al.
Publicado: (2017)

Regorafenib beyond the Second Line in Relapsed Glioblastoma: A Case Report and Literature Review
por: Pirozzi, Mario, et al.
Publicado: (2022)

Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis
por: Orditura, Michele, et al.
Publicado: (2016)

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
por: Franzese, Elisena, et al.
Publicado: (2020)

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis
por: FEDERICO, ALESSANDRO, et al.
Publicado: (2015)

Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population
por: Petrillo, Angelica, et al.
Publicado: (2020)

Implication of the Hedgehog pathway in hepatocellular carcinoma
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
por: Diana, Anna, et al.
Publicado: (2020)

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures
por: Della Corte, Carminia Maria, et al.
Publicado: (2019)

Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis
por: Ventriglia, J., et al.
Publicado: (2018)

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
por: Fasano, Morena, et al.
Publicado: (2022)

Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells
por: Ciaramella, Vincenza, et al.
Publicado: (2018)

Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience
por: Vitiello, Pietro Paolo, et al.
Publicado: (2019)

Mechanisms of resistance to EGFR-targeted drugs: lung cancer
por: Morgillo, Floriana, et al.
Publicado: (2016)

Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives
por: Ciaramella, Vincenza, et al.
Publicado: (2018)

Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis
por: Pompella, Luca, et al.
Publicado: (2020)

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab
por: Martini, Giulia, et al.
Publicado: (2022)

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
por: Vitiello, Pietro Paolo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ljh47eo11o5a13ht4g8rbljho9